ImmunoPrecise Antibodies (IPA) Return on Sales by Net Profit

Corporate emblem and logo of ImmunoPrecise Antibodies Ltd (IPA)

ImmunoPrecise Antibodies (IPA) is accelerating the development of biologics through innovative antibody discovery. The target net margin demonstrates effective cost management, with the -122.10 mark reflecting the current state. While robotics and AI screening are replacing manual labor, competitive pressure and a decline in external research orders create certain risks for the company's bottom line.

ImmunoPrecise Antibodies Ltd. (IPA) - Net Sales Margin from 07/04/2022 to 09/04/2025

immunoprecise.com - analytical breakdowns and key metrics (IPA)

- share price and expert price forecast:
Analysis of all company metrics:ImmunoPrecise Antibodies - IPA
Finished products of ImmunoPrecise Antibodies

This indicator serves as a key filter to separate temporary fluctuations from the asset's long-term potential. The metric calculates the share of net profit in total revenue, reflecting the actual efficiency of business monetization. By analyzing the sales margin level, an investor determines the capital's resilience to market recessions. Growth in these indicators confirms a high return on investment in advanced laboratories. The loyalty of antibody engineering experts converts directly into the operating profitability of ImmunoPrecise Antibodies (IPA).

Direct competitors

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|EDIT (editasmedicine.com) - Net Sales Margin|Net Margin SLN|Net Margin ProQR Therapeutics NV (PRQR)|Codexis - Net Return on Sales|Net Margin Sangamo SGMO|NAUT: Net Return on Sales|MGX: Return on Sales by Net Profit|Net Margin Precision BioSciences|GBIO (generationbio.com) - Return on Sales by Net Profit|Net Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Net Sales Margin|Net Return on Sales IMNN (Imunon, Inc.)|Net Sales Margin PHIO|MBIO - Net Margin|Net Sales Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Net Margin|Applied DNA - Net Sales Margin|Net Margin Bluebird Bio|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX